Semaglutide, also known as Wegovy or Ozempic, has been given approval by the Food and Drug Administration for the treatment of chronic weight control. Semaglutide treatments are given subcutaneously by our experienced and trained medical professionals.
Semaglutide is a GLP-1 agonist and was first approved in the U.S in 2017 as a method to improve glycemic control in patients with Type 2 diabetes. Recently, once weekly high-dose Semaglutide has shown to be an effective solution for patients who are having difficulty losing weight. It now carries a FDA indication as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in overweight or obese adult patients.
Semaglutide, a medicine that raises the body’s levels of glucagon-like peptide, is typically administered subcutaneously once per week during the patient’s treatment. GLP-1 is a vital factor in controlling blood sugar and weight. It aids in appetite suppression through the brain and delays stomach emptying to heighten the feeling of fullness.
GLP-1 is a hormone produced in the small intestine that stimulates insulin secretion and inhibits glucagon secretion, thereby lowering blood sugar. Shorter-acting agonists of the GLP-1 receptor are particularly effective at lowering post-meal glucose spikes, whereas longer-acting GLP-1 agonists have a balanced effect on lowering post-meal glucose levels as well as fasting glucose levels.This GLP-1 agonist has demonstrated beneficial effects on hyperglycemia in addition to decreased appetite and reduced daily caloric intake.
Patients with obesity and excess weight who have a BMI of 30 or higher, or a BMI of 27 or higher with an additional obesity-related health issue, are eligible for Semaglutide. Semaglutide alone is unlikely to achieve the desired result of weight reduction; it is meant to support a routine of increased physical activity and a low-calorie diet.
A consistent physical exercise routine, nutritional assistance, and good eating practices are necessary for weight loss with Semaglutide. The program starts with an initial dietary consultation followed by an initial medication consultation to examine your medical history, talk about your weight reduction objectives, and assess if Semaglutide is the right therapy for you.
We accept patients anywhere in Virginia or Maryland including Aldie, Alexandria, Ashburn, Herndon, Leesburg, Manassas, Reston, Stone Ridge, Warrenton, Winchester, Baltimore, Columbia, Germanton, Silver Spring, Frederick, Gaithersburg and Bethesda.
Book Now